Breaking Finance News

Zacks Investment Research downgraded GenVec Inc (NASDAQ:GNVC) to Hold in a report released today.

Zacks Investment Research has downgraded GenVec Inc (NASDAQ:GNVC) to Hold in a report released on 10/10/2016.

Previously on Wednesday October 05, 2016, Zacks Investment Research reported about GenVec Inc (NASDAQ:GNVC) raised the target price from $0.00 to $0.50. At the time, this indicated a possible upside of 0.19%.

Yesterday GenVec Inc (NASDAQ:GNVC) traded -2.38% lower at $0.41. The company’s 50-day moving average is $0.53 and its 200-day moving average is $0.63. The last stock close price is down -35.14% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 42,531 shares of the stock were exchanged, down from an average trading volume of 144,069

See Chart Below


GenVec Inc has a 52 week low of $0.35 and a 52 week high of $3.69 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its target price, a total of 1 firm has reported on the stock. The consensus target price is $5.00 with 0 firms rating the stock a strong buy, 0 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About GenVec Inc (NASDAQ:GNVC)

GenVec, Inc. (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company's development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria. In the area of animal health, it is developing vaccines against foot-and-mouth disease (FMD). The Company develops and commercializes its product candidates through collaborations. The Company's lead product candidate is CGF166. The Company's vaccine candidates include preventative vaccines against RSV and malaria, and a therapeutic vaccine for HSV. The Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.